SG11201507763RA - 5-amino-quinoline-8-carboxamide derivatives as 5-ht4 receptor agonists - Google Patents

5-amino-quinoline-8-carboxamide derivatives as 5-ht4 receptor agonists

Info

Publication number
SG11201507763RA
SG11201507763RA SG11201507763RA SG11201507763RA SG11201507763RA SG 11201507763R A SG11201507763R A SG 11201507763RA SG 11201507763R A SG11201507763R A SG 11201507763RA SG 11201507763R A SG11201507763R A SG 11201507763RA SG 11201507763R A SG11201507763R A SG 11201507763RA
Authority
SG
Singapore
Prior art keywords
quinoline
amino
receptor agonists
carboxamide derivatives
carboxamide
Prior art date
Application number
SG11201507763RA
Other languages
English (en)
Inventor
Ramakrishna Nirogi
Anil Karbhari Shinde
Venkateswarlu Jasti
Original Assignee
Suven Life Sciences Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Suven Life Sciences Ltd filed Critical Suven Life Sciences Ltd
Publication of SG11201507763RA publication Critical patent/SG11201507763RA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/558Immunoassay; Biospecific binding assay; Materials therefor using diffusion or migration of antigen or antibody
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407Specifically defined cancers
    • G01N33/57426Specifically defined cancers leukemia
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/82Translation products from oncogenes
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/52Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Oncology (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Epidemiology (AREA)
SG11201507763RA 2013-03-20 2013-10-18 5-amino-quinoline-8-carboxamide derivatives as 5-ht4 receptor agonists SG11201507763RA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/IN2013/000639 WO2014147636A1 (en) 2013-03-20 2013-10-18 5-amino-quinoline-8-carboxamide derivatives as 5-ht4 receptor agonists
IN1199CH2013 IN2013CH01199A (zh) 2013-03-20 2013-10-18

Publications (1)

Publication Number Publication Date
SG11201507763RA true SG11201507763RA (en) 2015-10-29

Family

ID=54325095

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201507763RA SG11201507763RA (en) 2013-03-20 2013-10-18 5-amino-quinoline-8-carboxamide derivatives as 5-ht4 receptor agonists

Country Status (19)

Country Link
US (1) US9790211B2 (zh)
EP (1) EP2976337B1 (zh)
JP (1) JP6185650B2 (zh)
KR (1) KR101815307B1 (zh)
CN (1) CN105164119B (zh)
AP (1) AP2015008742A0 (zh)
AU (1) AU2013382944B2 (zh)
BR (1) BR112015024060A2 (zh)
CA (1) CA2907620C (zh)
DK (1) DK2976337T3 (zh)
EA (1) EA029365B1 (zh)
ES (1) ES2674993T3 (zh)
HK (1) HK1217483A1 (zh)
IN (1) IN2013CH01199A (zh)
MX (1) MX364929B (zh)
NZ (1) NZ712369A (zh)
SG (1) SG11201507763RA (zh)
WO (1) WO2014147636A1 (zh)
ZA (1) ZA201506804B (zh)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3265459B1 (en) * 2015-02-13 2019-05-15 Suven Life Sciences Limited Amide compounds as 5-ht4 receptor agonists
CN109444301A (zh) * 2018-12-18 2019-03-08 江苏省中医院 一种测定血浆中普芦卡必利浓度的方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU5150393A (en) * 1992-10-13 1994-05-09 Smithkline Beecham Plc Heterocyclic -esters or -amides used as 5-ht4 receptor antagonists
NZ257545A (en) 1992-11-05 1997-01-29 Smithkline Beecham Plc Heterocyclic (especially piperidine) derivatives and pharmaceutical compositions
FR2756564B1 (fr) * 1996-12-04 2004-05-14 Synthelabo Derives d'acide quinoleine-8-carboxylique, leur preparation et leur application en therapeutique
AU2001225664A1 (en) * 2000-06-15 2001-12-24 Respiratorius Ab 5-ht3 receptor antagonists for treatment of disorders involving airway constriction
PT1638959E (pt) * 2003-06-19 2007-12-12 Janssen Pharmaceutica Nv 4-(aminometil)piperidinobenzamidas antagonistas de 5ht4
US7964727B2 (en) 2003-11-24 2011-06-21 Pfizer Inc. Quinolonecarboxylic acid compounds having 5-HT4 receptor agonistic activity
US7834010B2 (en) 2003-12-23 2010-11-16 Serodus As Modulators of peripheral 5-HT receptors
WO2005092882A1 (en) * 2004-03-01 2005-10-06 Pfizer Japan, Inc. 4-amino-5-halogeno-benzamide derivatives as 5-ht4 receptor agonists for the treatment of gastrointestinal, cns, neurological and cardiovascular disorders
DK1856114T3 (en) 2005-02-25 2014-11-17 Raqualia Pharma Inc Benzisoxazol-DERIVATIVES
ES2333545T3 (es) 2005-07-22 2010-02-23 Pfizer, Inc. Derivados de indazolcarboxamida como agonistas de receptores 5ht4.
GB0525661D0 (en) * 2005-12-16 2006-01-25 Glaxo Group Ltd Novel compounds
US8980922B2 (en) * 2010-02-12 2015-03-17 Raqualia Pharma Inc. 5-HT4 receptor agonists for the treatment of dementia
MX2012008721A (es) 2010-02-16 2012-08-17 Pfizer (r)-4-((4-((4-(tetrahidrofuran-3-iloxi)benzo[d]isoxazol-3-iloxi)m etil) tetrahidro-2h-piran-4-ol, un agonista pacial de receptores 5-ht4.

Also Published As

Publication number Publication date
EA201591844A1 (ru) 2016-08-31
WO2014147636A8 (en) 2014-12-04
ES2674993T3 (es) 2018-07-05
NZ712369A (en) 2016-11-25
EP2976337A1 (en) 2016-01-27
DK2976337T3 (en) 2018-07-16
KR20160004274A (ko) 2016-01-12
CA2907620A1 (en) 2014-09-25
US9790211B2 (en) 2017-10-17
AP2015008742A0 (en) 2015-09-30
JP2016516089A (ja) 2016-06-02
AU2013382944B2 (en) 2016-08-04
EP2976337B1 (en) 2018-05-02
CN105164119A (zh) 2015-12-16
BR112015024060A2 (pt) 2017-07-18
AU2013382944A1 (en) 2015-10-08
KR101815307B1 (ko) 2018-01-04
WO2014147636A1 (en) 2014-09-25
JP6185650B2 (ja) 2017-08-23
US20160280694A1 (en) 2016-09-29
CA2907620C (en) 2018-03-13
MX364929B (es) 2019-05-14
HK1217483A1 (zh) 2017-01-13
MX2015012350A (es) 2016-05-09
CN105164119B (zh) 2017-12-08
ZA201506804B (en) 2016-07-27
EA029365B1 (ru) 2018-03-30
IN2013CH01199A (zh) 2015-08-14

Similar Documents

Publication Publication Date Title
HK1215795A1 (zh) 鵝膏毒素衍生物
SG11201506100XA (en) Pyridazinone-amides derivatives
HK1217294A1 (zh) '- '- '-氟- '-甲基取代的核苷衍生物
HRP20181141T1 (hr) Derivati purina kao agonisti cb2 receptora
ZA201601333B (en) Oxoquinazolinyl-butanamide derivatives
SG11201605189YA (en) Imidazopyrazinone derivatives
IL245948B (en) 5–ht4 indazole compounds as receptor agonists
HK1213566A1 (zh) 新的四唑酮衍生物
HK1217483A1 (zh) 作爲 受體激動劑的 -氨基-喹啉- -甲酰胺衍生物
IL243730A0 (en) Vasopressin-2 receptor agonists
GB201312010D0 (en) Receptor Agonists